Literature DB >> 19252177

Slow responses to standard dose rituximab in immune thrombocytopenic purpura.

Kevin Kelly, Mary Gleeson, Philip Thomas Murphy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19252177      PMCID： PMC2649358          DOI： 10.3324/haematol.2008.001396

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy.

Authors: 
Journal:  Br J Haematol       Date:  2003-02       Impact factor: 6.998

Review 2.  Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications.

Authors:  Kiarash Kojouri; Sara K Vesely; Deirdra R Terrell; James N George
Journal:  Blood       Date:  2004-06-24       Impact factor: 22.113

3.  Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia.

Authors:  Francesco Zaja; Nicola Vianelli; Marta Battista; Alessandra Sperotto; Francesca Patriarca; Valentina Tomadini; Carla Filì; Monica Tani; Michele Baccarani; Renato Fanin
Journal:  Exp Hematol       Date:  2006-05       Impact factor: 3.084

Review 4.  Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.

Authors:  Donald M Arnold; Francesco Dentali; Mark A Crowther; Ralph M Meyer; Richard J Cook; Christopher Sigouin; Graeme A Fraser; Wendy Lim; John G Kelton
Journal:  Ann Intern Med       Date:  2007-01-02       Impact factor: 25.391

5.  Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

Authors:  R Stasi; A Pagano; E Stipa; S Amadori
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

6.  Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.

Authors:  Francesco Zaja; Marta Lisa Battista; Maria Teresa Pirrotta; Salvatore Palmieri; Michela Montagna; Nicola Vianelli; Luciana Marin; Margherita Cavallin; Monica Bocchia; Marzia Defina; Micaela Ippoliti; Felicetto Ferrara; Francesca Patriarca; Maria Antonietta Avanzini; Mario Regazzi; Michele Baccarani; Miriam Isola; Franca Soldano; Renato Fanin
Journal:  Haematologica       Date:  2008-04-09       Impact factor: 9.941

7.  Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.

Authors:  Bertrand Godeau; Raphael Porcher; Olivier Fain; François Lefrère; Pierre Fenaux; Stéphane Cheze; Anne Vekhoff; Marie-Paule Chauveheid; Jerôme Stirnemann; Lionel Galicier; Emmanuelle Bourgeois; Stéphanie Haiat; Bruno Varet; Michel Leporrier; Thomas Papo; Mehdi Khellaf; Marc Michel; Philippe Bierling
Journal:  Blood       Date:  2008-05-07       Impact factor: 22.113

8.  Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura.

Authors:  R Stasi; E Stipa; M Masi; M Cecconi; M T Scimò; F Oliva; A Sciarra; A P Perrotti; G Adomo; S Amadori
Journal:  Am J Med       Date:  1995-05       Impact factor: 4.965

Review 9.  Rituximab in the treatment of autoimmune haematological disorders.

Authors:  Bernadette Garvey
Journal:  Br J Haematol       Date:  2008-03-03       Impact factor: 6.998
  9 in total
  4 in total

1.  Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia.

Authors:  Zhenyu Li; Weiwei Mou; Guang Lu; Jiang Cao; Xupeng He; Xiuying Pan; Kailin Xu
Journal:  Int J Hematol       Date:  2010-12-29       Impact factor: 2.490

2.  Low Dose Rituximab in Chronic ITP: Still an Option in Resource Limited Settings.

Authors:  Rajan Kapoor; Rajiv Kumar; M Mahapatra; H P Pati; Suman Kumar Pramanik
Journal:  Indian J Hematol Blood Transfus       Date:  2016-12-19       Impact factor: 0.900

3.  Efficiency of treatment with rituximab in platelet transfusion refractoriness: a study of 7 cases.

Authors:  Wenbin Liu; Dijiong Wu; Tonglin Hu; Baodong Ye
Journal:  Int J Clin Exp Med       Date:  2015-08-15

4.  M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study.

Authors:  Leona E Ling; Jan L Hillson; Renger G Tiessen; Tjerk Bosje; Mattheus Paulus van Iersel; Darrell J Nix; Lynn Markowitz; Nicholas A Cilfone; Jay Duffner; James B Streisand; Anthony M Manning; Santiago Arroyo
Journal:  Clin Pharmacol Ther       Date:  2018-12-04       Impact factor: 6.875
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.